Summary
The product Primobolan 150 mg/ml, manufactured by ACE Pharmaceutical Solutions, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number PBL013, was submitted by the manufacturer AcePharma and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Methanolone Enanthate, with a concentration of 139.36 mg/ml, which is 7.09% below the labeled claim of 150 mg/ml.
The testing process began on 15 December 2023, with the sample received on 29 December 2023, and analysis completed on 3 January 2024. The results indicate underdosing, raising concerns about the consistency and reliability of the product. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: ACE Pharmaceutical Solutions
- Product Name: Primobolan 150 mg/ml
- Active Ingredient: Methanolone Enanthate
- Batch Number: PBL013
- Expiration Date: Not provided
- Delivery Method: Injectable.
Sample Acquisition and Testing
- Task Number: #37022
- Testing Ordered: 15 December 2023
- Sample Received: 29 December 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: ACE Pharmaceuticals (Manufacturer)
- Analysis Paid For By: ACE Pharmaceuticals (Manufacturer)
Testing Results
- Specification: 150 mg/ml (as stated on the label)
- Measured Concentration: 139.36 mg/ml
- Accuracy: 92.91% (7.09% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/37022_NNDU6YKVCD1Z
Evaluation of Manufacturer-Submitted Testing
This analysis highlights a significant underdosing issue with the tested product. The sample was submitted and funded by the manufacturer AcePharma, which may introduce potential biases. Manufacturer often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Primobolan 150 mg/ml is underdosed, with a measured concentration of 139.36 mg/ml. This result raises concerns about the quality control for this batch and underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
